Galidesivir (BCX 4430)
Galidesivir (BCX 4430) was developed by BioCryst Pharmaceuticals with funding from NIAID and originally intended as a treatment for hepatitis. It is a viral RNA-dependent RNA polymerase (RdRp) inhibitor and has demonstrated broad-spectrum activity in multiple viruses and a favorable preliminary preclinical safety profile. It has been used in trials against Marburg Virus Disease, Yellow Fever and Filovirus Infections and Ebola Virus Infection.
Recommended customer products :
API's & Drug Standards
Cancer Research and Antivirals
|Price||Custom packed. Request price on line.|
|MDL Number||Request if not shown|
Send us your enquiry for Galidesivir (BCX 4430). We offer custom pack sizes at special prices. We aim to respond to your enquiry within 24 hours.
We value your input so if you have suggestions regarding new applications for Galidesivir (BCX 4430) email us and we will include your contribution on the website.